M28 Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

M28 Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-17,572	Closed	-$1.27M	–	13
2023 Q1	$1.27M	Hold	17,572	–	–	1.44%	12
2022 Q4	$1.44M	Buy	+17,572	New	+$1.83M	1.37%	12
2022 Q3	–	Sell	-10,770	Closed	-$2.1M	–	13
2022 Q2	$2.1M	Sell	10,770 -4,804	-31%	-$784K	2.35%	11
2022 Q1	$3.62M	Sell	15,574 -2,701	-15%	-$860K	3.33%	11
2021 Q4	$7.2M	Buy	+18,275	New	+$7.69M	5.62%	9

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

M28 Capital Management's ATRA Position: Q2 2023 in Review

M28 Capital Management sold out of Atara Biotherapeutics (ATRA) in Q2 2023, closing a stake of 17,572 shares — an estimated $1.27M sold.

M28 Capital Management first reported a position in ATRA in Q4 2021 and held it in 5 quarters. The position peaked at $7.2M in Q4 2021. 118 funds tracked by Wall St. Rank hold ATRA as of Q2 2023.

M28 Capital Management reported no remaining Atara Biotherapeutics position as of Q2 2023 after selling out during the quarter.
M28 Capital Management sold 17,572 Atara Biotherapeutics shares in Q2 2023, an estimated $1.27M.
M28 Capital Management first reported a position in Atara Biotherapeutics in Q4 2021 and held it in 5 quarters.
M28 Capital Management's Atara Biotherapeutics position peaked at $7.2M in Q4 2021.
118 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2023.

Based on M28 Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.